[
    {
        "id": "article-27833_245",
        "title": "Prostate Cancer -- Medical Oncology -- Aggressive Prostate Cancer",
        "content": "Aggressive disease in prostate cancer is typically defined as either locally advanced, a higher Gleason score (Gleason 4+4=8 or higher), or a rapid PSA doubling time of\u00a010 months or less. Treatment\u00a0for aggressive prostate cancers may involve radical prostatectomy, radiation therapy, HIFU, cryosurgery, hormonal therapy, chemotherapy, targeted therapy, immunotherapy, radiopharmaceuticals, or some combination of these. Early use of combinatorial therapies\u00a0is helpful in many patients presenting with aggressive or advanced, localized disease. [26] [296] [321]",
        "contents": "Prostate Cancer -- Medical Oncology -- Aggressive Prostate Cancer. Aggressive disease in prostate cancer is typically defined as either locally advanced, a higher Gleason score (Gleason 4+4=8 or higher), or a rapid PSA doubling time of\u00a010 months or less. Treatment\u00a0for aggressive prostate cancers may involve radical prostatectomy, radiation therapy, HIFU, cryosurgery, hormonal therapy, chemotherapy, targeted therapy, immunotherapy, radiopharmaceuticals, or some combination of these. Early use of combinatorial therapies\u00a0is helpful in many patients presenting with aggressive or advanced, localized disease. [26] [296] [321]"
    },
    {
        "id": "Surgery_Schwartz_11738",
        "title": "Surgery_Schwartz",
        "content": "boney structures. Modern CT PET scans have a limited role at this point.Treatment for localized prostate cancer is guided by can-cer aggressiveness and patient\u2019s preferences. Active sur-veillance is recommended for patients with low-risk disease grade 1\u20132, early-stage disease (cT1c), and small volume disease as determined by biopsy. Large prospective cohorts and randomized clinical trials have established the safety of this approach.134,135 The risk of progression to metastatic disease with close follow-up and repeat prostate biopsies is less than 2% in over 12 years. Radical prostatectomy and pelvic lymph node dissection (robotic, laparoscopic, or open), image modulated radiation therapy (IMRT), and brachytherapy are the standard of care for curative treatments. All provide equal cancer specific survival for low and intermediate risk cancers. For higher risk prostate cancer patients, both surgery and IMRT with androgen 8Figure 40-11. The da Vinci Surgical System used commonly for",
        "contents": "Surgery_Schwartz. boney structures. Modern CT PET scans have a limited role at this point.Treatment for localized prostate cancer is guided by can-cer aggressiveness and patient\u2019s preferences. Active sur-veillance is recommended for patients with low-risk disease grade 1\u20132, early-stage disease (cT1c), and small volume disease as determined by biopsy. Large prospective cohorts and randomized clinical trials have established the safety of this approach.134,135 The risk of progression to metastatic disease with close follow-up and repeat prostate biopsies is less than 2% in over 12 years. Radical prostatectomy and pelvic lymph node dissection (robotic, laparoscopic, or open), image modulated radiation therapy (IMRT), and brachytherapy are the standard of care for curative treatments. All provide equal cancer specific survival for low and intermediate risk cancers. For higher risk prostate cancer patients, both surgery and IMRT with androgen 8Figure 40-11. The da Vinci Surgical System used commonly for"
    },
    {
        "id": "wiki20220301en190_43919",
        "title": "Biochemical recurrence",
        "content": "Biochemical recurrence is a rise in the blood level of prostate-specific antigen (PSA) in prostate cancer patients after treatment with surgery or radiation. Biochemical recurrence may occur in patients who do not have symptoms. It may mean that the cancer has come back. Also called PSA failure and biochemical relapse. It is used to detect metastatic progression of the prostate cancer. References Further reading Guidelines:Prostate cancer/Management/Locally advanced and metastatic/Biochemical relapse alternative causes, and implications for treatment Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition 10 definitions compared. External links Biochemical recurrence entry in the public domain NCI Dictionary of Cancer Terms Oncology",
        "contents": "Biochemical recurrence. Biochemical recurrence is a rise in the blood level of prostate-specific antigen (PSA) in prostate cancer patients after treatment with surgery or radiation. Biochemical recurrence may occur in patients who do not have symptoms. It may mean that the cancer has come back. Also called PSA failure and biochemical relapse. It is used to detect metastatic progression of the prostate cancer. References Further reading Guidelines:Prostate cancer/Management/Locally advanced and metastatic/Biochemical relapse alternative causes, and implications for treatment Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition 10 definitions compared. External links Biochemical recurrence entry in the public domain NCI Dictionary of Cancer Terms Oncology",
        "wiki_id": "14416443"
    }
]